Fulvestrant Plus Abemaciclib With or Without Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer

Investigator: Jenny Chang, MD

Study Coordinator: Alexys Brock

Status: Enrolling

ClinicalTrials.gov Number: NCT05305924

Phone: 346.238.4814

Protocol Number: PRO00028925


The study will investigate if a one month drug holiday from the CDK4/6 inhibitor drug, abemaciclib, will restore the body's sensitivity to the drug and make the subsequent treatment of abemaciclib plus fulvestrant more effective.
More to Explore